Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of VX-433 in Healthy Participants
NCT07584434Phase 1Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-433 in narcolepsy type 1 (NT1) (5 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 18, Maximum Observed Plasma Concentration at Day 22 and 1 more. Started May 2026; status: recruiting.
02
Drugs
VX-433
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT07584434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584434.